---
title: "VEGFR2-targeted NIR-II fluorescent probe ICG-VTP for precise ovarian cancer imaging and surgical n"
id: "pubmed-42184579"
canonical_url: "https://medichelpline.com/clinical-feed/pubmed-42184579"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "PubMed / NCBI"
source_url: "https://pubmed.ncbi.nlm.nih.gov/42184579/"
doi: "10.1016/j.bioorg.2026.110017"
published_at: "2026-09-05T00:00:00.000Z"
evidence_level: "Journal Article"
license: "CC-BY-NC-4.0 / Informational Use"
---
# VEGFR2-targeted NIR-II fluorescent probe ICG-VTP for precise ovarian cancer imaging and surgical n
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/pubmed-42184579
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** PubMed / NCBI
- **Source URL:** [Original Journal Publication](https://pubmed.ncbi.nlm.nih.gov/42184579/)
- **DOI:** [10.1016/j.bioorg.2026.110017](https://doi.org/10.1016%2Fj.bioorg.2026.110017)
- **Published At:** 2026-09-05T00:00:00.000Z
- **Evidence Rating:** Journal Article
## Executive GIST (TL;DR)
- Molecular imaging of tumor biomarkers can improve precision diagnosis and intraoperative guidance; **VEGFR2** is a central regulator of tumor angiogenesis and an attractive imaging target. - The authors designed a novel VEGFR2-targeting peptide named VTP by combining the peptide K237 (HTMYYHHYQHHL), a flexible Ser-Ser-Ser linker, and an albumin-binding peptide (ABP, DICLPRWGCLWED) to extend circulation time. - Surface plasmon resonance (SPR) showed high affinity of VTP for **VEGFR2** with a dissociation constant (KD) of 15.4 nM. - VTP was conjugated to indocyanine green (ICG) to create the targeted fluorescent probe **ICG-VTP**, aiming to overcome ICG’s short half-life and lack of active targeting. - ABP modification conferred a longer blood half-life to the probe and promoted accumulation that correlated positively with VEGFR2 expression across multiple tumor models. - In vivo imaging in three tumor xenograft models—high VEGFR2 expression (SKOV3, ovarian), moderate (HCT116, colorectal), and low (A549, NSCLC)—demonstrated tumor-to-background ratios (TBR) at 10 h post-injection of 2.95, 2.05, and 1.42, respectively, supporting target-specific contrast. - The probe enabled intraoperative fluorescence navigation and facilitated precise tumor resection in the reported models. - Safety assessments reported no significant toxicity at the cellular or tissue levels in the study. - The authors conclude that **ICG-VTP** shows strong specificity and improved imaging contrast for VEGFR2-positive tumors and has potential for further biomedical research and clinical translation.
## Clinical Analysis & Structured Key Points
Clipboard, Search History, and several other advanced features are temporarily unavailable. [ Skip to main page content ](https://pubmed.ncbi.nlm.nih.gov/42184579/#article-details) ![U.S. flag](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png) An official website of the United States government Here's how you know ![Dot gov](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg) **The .gov means it’s official.** Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. ![Https](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg) **The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. [ ![NIH NLM Logo](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg) ](https://www.ncbi.nlm.nih.gov/) [Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42184579%2F) Show account info Close #### Account Logged in as: **username** * [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/) * [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/) * [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/) * [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/42184579/) [Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys) [NCBI Homepage](https://www.ncbi.nlm.nih.gov) [MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/) [Main Content](https://pubmed.ncbi.nlm.nih.gov/42184579/#maincontent) [Main Navigation](https://pubmed.ncbi.nlm.nih.gov/42184579/) [ ![pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/c24ab723-7c80-48cd-9c68-022ded852586/core/images/pubmed-logo-blue.svg) ](https://pubmed.ncbi.nlm.nih.gov/) [ ](https://pubmed.ncbi.nlm.nih.gov/42184579/ "Show search bar") Search: [](https://pubmed.ncbi.nlm.nih.gov/42184579/ "Clear search input")Search [Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/) [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/clipboard/) [ User Guide ](https://pubmed.ncbi.nlm.nih.gov/help/) Save Email Send to * [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/42184579/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42184579%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42184579%2F%23open-collections-panel) * [Citation manager](https://pubmed.ncbi.nlm.nih.gov/42184579/) Display options Display options Format Abstract PubMed PMID ## Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel ## Email citation Email address has not been verified. Go to [ My NCBI account settings ](https://account.ncbi.nlm.nih.gov/settings/) to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel ### Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42184579/) Add Cancel ### Add to My Bibliography * My Bibliography Unable to load your delegates due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42184579/) Add Cancel ## Your saved search Name of saved search: Search terms: [Test search terms](https://pubmed.ncbi.nlm.nih.gov/42184579/) Would you like email updates of new search results? Saved Search Alert Radio Buttons * Yes * No Email: ([change](https://www.ncbi.nlm.nih.gov/account/settings/)) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel ## Create a file for external citation management software Create file Cancel ## Your RSS Feed Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy ### Full text links [![Elsevier Science full text link](https://cdn.ncbi.nlm.nih.gov/corehtml/query/egifs/https:--linkinghub.elsevier.com-ihub-images-PubMedLink.gif) Elsevier Science ](https://linkinghub.elsevier.com/retrieve/pii/S0045-2068\(26\)00553-5 "See full text options at Elsevier Science") [ Full text links ](https://pubmed.ncbi.nlm.nih.gov/42184579/) ### Actions Cite Collections Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42184579/) Add Cancel Permalink Permalink Copy Display options Display options Format Abstract PubMed PMID ### Page navigation * [ Title & authors ](https://pubmed.ncbi.nlm.nih.gov/42184579/#heading) * [ Abstract ](https://pubmed.ncbi.nlm.nih.gov/42184579/#abstract) * [ Conflict of interest statement ](https://pubmed.ncbi.nlm.nih.gov/42184579/#conflict-of-interest) * [Similar articles](https://pubmed.ncbi.nlm.nih.gov/42184579/#similar) * [ MeSH terms ](https://pubmed.ncbi.nlm.nih.gov/42184579/#mesh-terms) * [ Substances ](https://pubmed.ncbi.nlm.nih.gov/42184579/#substances) * [Related information](https://pubmed.ncbi.nlm.nih.gov/42184579/#related-links) * [ LinkOut - more resources ](https://pubmed.ncbi.nlm.nih.gov/42184579/#linkout) Title & authors Abstract Conflict of interest statement Similar articles MeSH terms Substances Related information LinkOut - more resources Bioorg Chem Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Bioorg+Chem%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Bioorg+Chem%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42184579/) . 2026 Sep 5:179:110017. doi: 10.1016/j.bioorg.2026.110017. Epub 2026 May 22. # VEGFR2-targeted NIR-II fluorescent probe for precise imaging and surgical navigation of ovarian cancer [Nannan Tian](https://pubmed.ncbi.nlm.nih.gov/?term=Tian+N&cauthor_id=42184579)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42184579/#full-view-affiliation-1 "School of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, China."), [Shuxian Zhao](https://pubmed.ncbi.nlm.nih.gov/?term=Zhao+S&cauthor_id=42184579)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42184579/#full-view-affiliation-1 "School of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, China."), [Fan Xu](https://pubmed.ncbi.nlm.nih.gov/?term=Xu+F&cauthor_id=42184579)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42184579/#full-view-affiliation-2 "School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, China."), [Ruiqi Liu](https://pubmed.ncbi.nlm.nih.gov/?term=Liu+R&cauthor_id=42184579)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42184579/#full-view-affiliation-3 "State Key Laboratory of Drug Research, Molecular Imaging Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China."), [Wenhong Dong](https://pubmed.ncbi.nlm.nih.gov/?term=Dong+W&cauthor_id=42184579)[ 4 ](https://pubmed.ncbi.nlm.nih.gov/42184579/#full-view-affiliation-4 "Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, Shandong 264117, China."), [Zhaorui Song](https://pubmed.ncbi.nlm.nih.gov/?term=Song+Z&cauthor_id=42184579)[ 5 ](https://pubmed.ncbi.nlm.nih.gov/42184579/#full-view-affiliation-5 "Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, Shandong 264117, China. Electronic address: songzhaorui1016@163.com."), [Yongkuan Suo](https://pubmed.ncbi.nlm.nih.gov/?term=Suo+Y&cauthor_id=42184579)[ 6 ](https://pubmed.ncbi.nlm.nih.gov/42184579/#full-view-affiliation-6 "Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, Shandong 264117, China; State Key Laboratory of Drug Research, Molecular Imaging Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China. Electronic address: suoyongkuan@simm.ac.cn."), [Zhen Cheng](https://pubmed.ncbi.nlm.nih.gov/?term=Cheng+Z&cauthor_id=42184579)[ 7 ](https://pubmed.ncbi.nlm.nih.gov/42184579/#full-view-affiliation-7 "School of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, China; Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, Shandong 264117, China; State Key Laboratory of Drug Research, Molecular Imaging Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, China. Electronic address: zcheng@simm.ac.cn.") Affiliations Expand ### Affiliations * 1 School of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, China. * 2 School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, China. * 3 State Key Laboratory of Drug Research, Molecular Imaging Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China. * 4 Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, Shandong 264117, China. * 5 Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, Shandong 264117, China. Electronic address: songzhaorui1016@163.com. * 6 Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, Shandong 264117, China; State Key Laboratory of Drug Research, Molecular Imaging Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China. Electronic address: suoyongkuan@simm.ac.cn. * 7 School of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, China; Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, Shandong 264117, China; State Key Laboratory of Drug Research, Molecular Imaging Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, China. Electronic address: zcheng@simm.ac.cn. * PMID: **42184579** * DOI: [ 10.1016/j.bioorg.2026.110017 ](https://doi.org/10.1016/j.bioorg.2026.110017) Item in Clipboard # VEGFR2-targeted NIR-II fluorescent probe for precise imaging and surgical navigation of ovarian cancer Nannan Tian et al. Bioorg Chem. 2026. Show details Display options Display options Format Abstract PubMed PMID Bioorg Chem Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Bioorg+Chem%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Bioorg+Chem%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42184579/) . 2026 Sep 5:179:110017. doi: 10.1016/j.bioorg.2026.110017. Epub 2026 May 22. ### Authors [Nannan Tian](https://pubmed.ncbi.nlm.nih.gov/?term=Tian+N&cauthor_id=42184579)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42184579/#short-view-affiliation-1 "School of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, China."), [Shuxian Zhao](https://pubmed.ncbi.nlm.nih.gov/?term=Zhao+S&cauthor_id=42184579)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42184579/#short-view-affiliation-1 "School of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, China."), [Fan Xu](https://pubmed.ncbi.nlm.nih.gov/?term=Xu+F&cauthor_id=42184579)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42184579/#short-view-affiliation-2 "School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, China."), [Ruiqi Liu](https://pubmed.ncbi.nlm.nih.gov/?term=Liu+R&cauthor_id=42184579)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42184579/#short-view-affiliation-3 "State Key Laboratory of Drug Research, Molecular Imaging Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China."), [Wenhong Dong](https://pubmed.ncbi.nlm.nih.gov/?term=Dong+W&cauthor_id=42184579)[ 4 ](https://pubmed.ncbi.nlm.nih.gov/42184579/#short-view-affiliation-4 "Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, Shandong 264117, China."), [Zhaorui Song](https://pubmed.ncbi.nlm.nih.gov/?term=Song+Z&cauthor_id=42184579)[ 5 ](https://pubmed.ncbi.nlm.nih.gov/42184579/#short-view-affiliation-5 "Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, Shandong 264117, China. Electronic address: songzhaorui1016@163.com."), [Yongkuan Suo](https://pubmed.ncbi.nlm.nih.gov/?term=Suo+Y&cauthor_id=42184579)[ 6 ](https://pubmed.ncbi.nlm.nih.gov/42184579/#short-view-affiliation-6 "Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, Shandong 264117, China; State Key Laboratory of Drug Research, Molecular Imaging Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China. Electronic address: suoyongkuan@simm.ac.cn."), [Zhen Cheng](https://pubmed.ncbi.nlm.nih.gov/?term=Cheng+Z&cauthor_id=42184579)[ 7 ](https://pubmed.ncbi.nlm.nih.gov/42184579/#short-view-affiliation-7 "School of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, China; Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, Shandong 264117, China; State Key Laboratory of Drug Research, Molecular Imaging Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, China. Electronic address: zcheng@simm.ac.cn.") ### Affiliations * 1 School of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, China. * 2 School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, China. * 3 State Key Laboratory of Drug Research, Molecular Imaging Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China. * 4 Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, Shandong 264117, China. * 5 Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, Shandong 264117, China. Electronic address: songzhaorui1016@163.com. * 6 Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, Shandong 264117, China; State Key Laboratory of Drug Research, Molecular Imaging Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China. Electronic address: suoyongkuan@simm.ac.cn. * 7 School of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, China; Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, Shandong 264117, China; State Key Laboratory of Drug Research, Molecular Imaging Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, China. Electronic address: zcheng@simm.ac.cn. * PMID: **42184579** * DOI: [ 10.1016/j.bioorg.2026.110017 ](https://doi.org/10.1016/j.bioorg.2026.110017) Item in Clipboard Full text links Cite Display options Display options Format Abstract PubMed PMID ## Abstract Molecular imaging of tumor biomarkers represents a crucial direction for advancing precision cancer diagnosis and therapy. As a core regulator of tumor angiogenesis, VEGFR2 represents an ideal molecular imaging target. Herein, a novel VEGFR2-targeting peptide (HTMYYHHYQHHLSSSDICLPRWGCLWED, named as VTP) was designed and synthesized by conjugating a peptide K237 (HTMYYHHYQHHL), a flexible tripeptide linker (Ser-Ser-Ser, SSS), and an albumin-binding peptide (ABP, DICLPRWGCLWED). The surface plasmon resonance (SPR) analysis confirmed that VTP had high binding affinity for VEGFR2 (KD = 15.4 nM). Although indocyanine green (ICG) has been widely used in clinical practice, its short half-life and lack of active targeting ability significantly restrict its potential for intraoperative navigation. In this study, the VEGFR2-targeting peptide VTP was conjugated with ICG to successfully construct a targeted fluorescent probe, ICG-VTP. Owing to ABP modification, this probe exhibits a longer blood half-life and shows accumulation characteristics that are highly positively correlated with VEGFR2 expression levels in multiple tumor models, including ovarian cancer, colorectal cancer, and non-small cell lung cancer. The probe yielded tumor-to-background ratios (TBR) of 2.95, 2.05, and 1.42 in high (SKOV3), moderate (HCT116), and low (A549) VEGFR2-expressing tumors at 10 h post-injection, respectively, confirming its specificity for VEGFR2 imaging. Further, the ICG-VTP probe enabled successful intraoperative fluorescence navigation and precise tumor resection. Safety assessments revealed no significant toxicity at cellular or tissue levels. In summary, the ICG-VTP probe demonstrates strong specificity and superior imaging contrast of VEGFR2-positive tumors, underscoring its high potential to advance biomedical research and clinical translation. **Keywords:** NIR-II fluorescence imaging; Surgical navigation; VEGFR2-targeting peptide; Vascular endothelial growth factor receptor 2 (VEGFR2). Copyright © 2026 Elsevier Inc. All rights reserved. [PubMed Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) ## Conflict of interest statement Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. ## Similar articles * [ Novel HER2-Targeted Peptide for NIR-II Imaging of Tumor. ](https://pubmed.ncbi.nlm.nih.gov/36668683/) Cao R, Li R, Shi H, Liu H, Cheng Z.Cao R, et al.Mol Pharm. 2023 Feb 6;20(2):1394-1403. doi: 10.1021/acs.molpharmaceut.2c00964. Epub 2023 Jan 20.Mol Pharm. 2023.PMID: 36668683 * [ PSMA-targeted fluorescent probe for NIR-II imaging in prostate cancer intraoperative navigation and tumor margin mapping. ](https://pubmed.ncbi.nlm.nih.gov/41799210/) Jiang Z, Tan H, Wu B, Zhang L, Kadeerhan G, Zhang J, Jin J, Zhang Z, Guo H, Guo W, Jia J, Tian J, Tang BZ, Wang D.Jiang Z, et al.Theranostics. 2026 Feb 11;16(9):4551-4565. doi: 10.7150/thno.117540. eCollection 2026.Theranostics. 2026.PMID: 41799210Free PMC article. * [ Fibroblast activation protein peptide-targeted NIR-I/II fluorescence imaging for stable and functional detection of hepatocellular carcinoma. ](https://pubmed.ncbi.nlm.nih.gov/39836214/) Lin E, Song M, Wang B, Shi X, Zhao J, Fu L, Bai Z, Zou B, Zeng G, Zhuo W, Li P, Cai C, Cheng Z, Hu Z, Li J.Lin E, et al.Eur J Nucl Med Mol Imaging. 2025 May;52(6):2157-2170. doi: 10.1007/s00259-025-07093-6. Epub 2025 Jan 21.Eur J Nucl Med Mol Im
## Related Clinical Research

- [Predicting Cancer Immunotherapy Response Using Dynamic CD8+ T Cell Changes — Pan‑Cancer Retrospect](https://medichelpline.com/clinical-feed/frontiers-in-immunology-13-a-predictive-model-for-immunotherapy-efficacy-in-cancer-based-on-dynamic.md)
- [Hereditary Cancer Genetic Testing in the Asian Indian Population: A 10-Year Retrospective Preprint](https://medichelpline.com/clinical-feed/medrxiv-14-a-decade-of-hereditary-cancer-genetic-testing-results-in-asian-indian.md)
- [Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)](https://medichelpline.com/clinical-feed/clinicaltrials-nct05489211.md) (DOI: NCT05489211)
- [Diabetes Mellitus and Cancer Risk: Epidemiology and Molecular Mechanisms](https://medichelpline.com/clinical-feed/pubmed-42364319.md) (DOI: 10.1016/j.bbrc.2026.154205)
- [CDCTNet: Transformer–CNN hybrid for colorectal lesion diagnosis](https://medichelpline.com/clinical-feed/plos-one-7-colorectal-lesion-diagnosis-using-transformer-and-deep-learning-with-multiscale.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.